Advanced Enzyme Technologies Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹297

Market cap₹3.7K Cr

P/E24.0

Published26 Aug 2026

What the Q1 FY27 call signalled

2 of 4 strong

RevenueRank 3

MarginRank 3

CapexYes

Order bookYes

Not discussed on this call: fundraise.

The short version

The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results. The company expects to achieve double-digit revenue growth for the full year, aiming for around 12%+ growth in the remaining quarters. - Growth trajectory is expected to improve in upcoming quarters after a relatively slower Q1. - EBITDA margins are anticipated to normalize to around 30-32% as operational efficiencies improve and energy costs stabilize. - R&D investment will increase to support sustained growth and margin improvement, though immediate margin expansion is not expected. - The U.S.

From Advanced Enzyme Technologies Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Rank 3

The company expects to achieve double-digit growth in the coming quarters despite some sales reversals affecting recent results.
Growth in the U.S. market is projected at around 8-10%, driven by branding efforts and gradual strategic changes rather than immediate product launches.
The business model focuses on sustained growth with a steady customer base, with 70-80% customers being consistent and 20-30% changing.
Growth is expected to come from a combination of new and existing products across various segments.
Biocatalysis is considered a high-growth segment, with good growth anticipated particularly in the second half of the year.
The company is investing in R&D to foster new product development and enhance productivity, supporting future growth.
Incremental sales reversals (around INR 10 crore) from a recent quarter are expected to be realized in subsequent quarters, supporting overall growth.

Profitability & Margins

The company expects to achieve double-digit revenue growth for the full year, aiming for around 12%+ growth in the remaining quarters.
Growth trajectory is expected to improve in upcoming quarters after a relatively slower Q1.
EBITDA margins are anticipated to normalize to around 30-32% as operational efficiencies improve and energy costs stabilize.
R&D investment will increase to support sustained growth and margin improvement, though immediate margin expansion is not expected.
The U.S. market is projected to grow steadily at 8-10% annually.
The growth will be driven by a combination of new and existing products across segments.
Working capital investment remains stable, with inventory and receivables closely managed.
The company is also focused on building a sticky business through brand recognition, which can support long-term profitability and earnings stability.

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

The company plans a total CapEx of INR 123 crore as discussed in the AGM.
Approximately INR 20 crore is for normal capital expenditure, INR 50 crore will be for R&D (work in progress), and the remaining is for growth.
The CapEx is expected to span FY27, with about INR 20 crore possibly extending into Q2 FY27.
The growth CapEx is not allocated to any specific segment but supports manufacturing enzymes for various industries.
Current fermentation capacity utilization is around 70-75%, prompting potential capacity expansion.
Plans to increase capacity will be taken up in the next quarter.
R&D expenditure is targeted to increase productivity and sustain growth but is not expected to immediately boost growth.
Overall, the CapEx represents a step-up compared to previous years to support sustained business growth.

Fundraising & Capital Structure

The transcript does not mention any current or planned fundraising through debt or equity.
There is discussion about a buyback of approximately 1.4 million shares (open-market buyback starting August 14), not a fundraising.
No references to raising capital via new debt or equity issuance during the call.
CapEx plans of around INR 123 crores for FY27 are highlighted, with no indication of financing method.
The company seems focused on operational efficiencies and internal funding for growth and R&D.
Thus, no explicit plans for future fundraising via debt or equity were shared in this earnings call.

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes

The transcript does not provide explicit details on the current or expected order book or pending orders in precise numbers.
Mukund Kabra mentions variability of 20-30% in customers quarter-on-quarter, indicating some order fluctuation.
There’s mention of some inventory and order-related delays or complexities at the customer level.
Mukund Kabra signals optimism about a "robust pipeline of sales orders" going forward.
He advises not to focus heavily on quarter-on-quarter fluctuations as order sizes may vary, with some quarters seeing quick sales and others less.
Overall, the management expects a strong momentum from the next quarter.
No exact quantitative data on order book or pending orders is provided on page 20 or surrounding context.

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAdvanced Enzyme Technologies Ltd

Rev 3Mar 3

See where Advanced Enzyme Technologies Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Advanced Enzyme's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q1 FY27 results?

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

The company plans a total CapEx of INR 123 crore as discussed in the AGM.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.